Anti Malarial.

Acute malaria, prophylaxis of malaria, rheumatoid arthritis, extra-intestinal amoebiasis, giardiasis, discoid lupus erythematosus and infectious mononucleosis.

Malaria. Acute Attack : Initially 600 mg base followed by 300 mg base after 6-8 hours on day 1. On days 2 and 3, single dose of 300 mg base / day.

Children : Initially 10 mg base / kg (max 600 mg base) followed by 5 mg base / kg (max 300 mg base) after 6 hours. Single doses of 5 mg base / kg on days 2 and 3.

Nausea, epigastric distress, vomiting, itching and headache. Chronic therapy may cause loss of vision due to retinal damage. Corneal opacities may occur but are reversible. Skin rash, photoallergy, myopathy, loss of hearing and graying of hair. Parenteral administration may lead to hypertension and cardiac depression.

G6PD deficiency, peripheral neuropathy, visual field charting is required during prolonged therapy. Irreversible retinal damage has been observed with long-term or high dosages. In children, the administered dosage should not be more than 5 mg / kg body weight.

Eye dysfunction, liver disease, severe haematological and GI disease.

Nausea, epigastric distress, vomiting, itching and headache. Chronic therapy may cause loss of vision due to retinal damage. Corneal opacities may occur but are reversible. Skin rash, photoallergy, myopathy, loss of hearing and graying of hair. Parenteral administration may lead to hypertension and cardiac depression.

Viviaquino tablets should be stored in a cool and dark place.